查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球基因組編輯市場：關注技術分佈：行業趨勢和預測（2023-2035）
市場調查報告書
商品編碼
1411406

全球基因組編輯市場：關注技術分佈：行業趨勢和預測（2023-2035）

Genome Editing Market: Focus on Technology-Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Key Geographical Regions & Distribution: Industry Trends & Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 270 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2023年，全球基因組編輯市場規模為35億美元，預計在預測期內（2023-2035年）複合年增長率為12.6%。

基因編輯（基因替換）是修改（插入、刪除、替換）生物體基因組中單一基因（或基因序列）的過程。近年來，編輯基因組內特定位點的需求不斷增加，基因編輯公司推出了多種基因組編輯工具——ZFN（鋅指核酸□）、TALEN（組織脂肪樣效應核酸□）以及最近的 CRISPR （基於cRNA的技術）等-發展正在迅速增加。這些基因編輯工具用於治療鐮狀細胞疾病（SCD）、帕金森氏症（PDD）、聽力損失（HELP）、週邊動脈疾病（PAD）、脊髓性肌肉萎縮症（SMA）和自體免疫疾病（AML ）等疾病. 它已被廣泛用作治療由遺傳異常引起的臨床症狀的糾正策略。人們正在努力創建標靶基因編輯療法，截至2023年，已有超過300種基因療法候選藥物正在進行臨床試驗。值得注意的是，預防性治療也是基因編輯應用市場感興趣的領域。但必須指出的是，基因編輯藥物的開發涉及基因研究領域的大量投資。為了有效率、準確和安全地提供這些藥物，製藥公司正在依賴基因組編輯公司開發的新基因組編輯技術，從而透過實現必要的基因操作來改善臨床結果，這將有助於藥物開發商的努力。憑藉令人鼓舞的臨床試驗結果和加速的藥物審批，基因組編輯市場預計在未來幾年將顯著成長。

本報告對全球基因組編輯市場進行了分析，並概述了治療方法、市場的基本結構和最新情況、主要的市場促進和限制因素、整體市場規模的趨勢展望以及按地區（所有三個我們調查各細分市場的詳細趨勢、主要業務聯盟和資本交易（投資、併購等）的近期動向、專利註冊狀況、當前競爭狀況、主要公司概況等。

主要市場參與者

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G+FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies
  • OXGENE
  • Prime Medicine
  • Revvity (formerly known as Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

目錄

第一章簡介

第二章研究方法

第 3 章. 經濟和其他專案特定考慮因素

第 4 章執行摘要

第 5 章 簡介

  • 基因組編輯概述
  • 基因組編輯技術的應用
  • 其他新興技術
  • 結論

第六章 技術情況

  • 基因組編輯：技術前景
  • 基因組編輯：技術開發人員現狀

第七章技術競爭力分析

  • 先決條件/關鍵參數
  • 調查方法
  • 技術競爭力分析

第八章公司簡介

  • Arcturus Therapeutics
  • Beam Therapeutics
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Graphite Bio
  • Intellia Therapeutics
  • Prime Medicine
  • Vor Biopharma
  • 其他主要公司

第 9 章 夥伴關係與合作

  • 合作模式
  • 基因組編輯技術：夥伴關係與合作

第10章 專利分析

  • 分析範圍/方法
  • 基因組編輯領域：專利分析
  • 基因組編輯領域：專利基準分析
  • 專利估值分析

第十一章 融資與投資分析

  • 基金類型
  • 基因組編輯領域：資金與投資分析

第十二章市場影響分析：驅動因素、限制因素、機會、挑戰

  • 市場驅動力
  • 市場制約因素
  • 市場機會
  • 市場挑戰
  • 結論

第十三章 基因組編輯技術市場

  • 假設和研究方法
  • 基因組編輯技術市場：未來預測（2023-2035）
  • 主要細分市場
  • 動態儀表板

第十四章 基因組編輯技術市場：依基因編輯技術類型劃分

  • 主要假設及研究方法
  • CRISPR-Cas系統：預測值（2023-2035）
  • TALEN：預測值（2023-2035）
  • 大範圍核酸□：預測值 (2023-2035)
  • ZFN：預測值（2023-2035）
  • 其他方法：預測值（2023-2035）
  • 測量數據

第十五章基因組編輯技術市場：依治療類型

  • 主要假設及研究方法
  • 細胞療法：預測值（2023-2035）
  • 基因治療：預測值（2023-2035）
  • 其他治療：預測值（2023-2035）
  • 測量數據

第十六章 基因組編輯技術市場：依基因編輯方法

  • 主要假設及研究方法
  • 基因敲除方法：預測價值（2023-2035）
  • 基因敲入方法：預測價值（2023-2035）
  • 測量數據

第十七章 基因組編輯技術市場：以基因傳遞方式

  • 主要假設及研究方法
  • 體外遞送方法：預測值（2023-2035）
  • 體內遞送方法：預測值（2023-2035）
  • 測量數據

第十八章 基因組編輯技術市場：以基因轉殖方式

  • 主要假設及研究方法
  • 病毒載體：預測值（2023-2035）
  • 非病毒載體：預測值（2023-2035）
  • 測量數據

第十九章 基因組編輯技術市場：依應用領域

  • 主要假設及研究方法
  • 藥物發現與開發：預測值（2023-2035）
  • 診斷：預測值（2023-2035）
  • 測量數據

第 20 章 基因組編輯技術市場：依最終使用者類型

  • 主要假設及研究方法
  • 製藥和生物技術公司：預測（2023-2035）
  • 學術/研究機構：預測值（2023-2035）
  • 測量數據

第21章基因組編輯技術市場：依主要地區

  • 主要假設及研究方法
  • 北美：預計價值（2023-2035）
  • 歐洲：預計值（2023-2035）
  • 亞太地區：預計價值（2023-2035）
  • 測量數據

第22章基因組編輯技術市場：按所使用的支付方式類型

  • 主要假設及研究方法
  • 裡程碑付款：預測值（2023-2035）
  • 預付款：預測（2023-2035）
  • 測量數據

第23章 基因組編輯技術市場：主要市場參與者

  • 產業龍頭企業

第24章結論

第25章管理見解

第26章附錄1：表格數據

第二十七章 附錄2：公司和組織名單

簡介目錄
Product Code: RA100464

The genome editing marketis valued at USD 3.5 billion in 2023 growing at a CAGR of 12.6% during the forecast period 2023-2035.

Gene editing or gene replacement is the process of modifying (inserting, deleting or replacing) a single gene (or a sequence of genes) in the genome of a living organism. In recent years, the need to edit at a specific site within the genome has increased, there has been a surge in the development of different types of genome editing tools by gene-editing companies. These include ZFNs (zinc finger nucleases), TALENs (tissue-aliphatic-like-effector nucleases) and, most recently, CRISPR (cRNA-based technology). These gene-editing tools have been widely used as a corrective strategy to treat clinical conditions resulting from genetic abnormalities, including Sickle cell disease (SCD), Parkinson's disease (PDD), hearing loss (HELP), peripheral artery disease (PAD), spinal muscular atrophies (SMA), autoimmune diseases (AML) and other types of genetic disorders. In the midst of the current efforts to create targeted gene-editing therapies, there are more than 300 candidates for gene therapy in clinical trials as of 2023. It is worth mentioning, prophylaxis treatment is another segment that has attracted a lot of attention in the market of gene editing applications. However, it is important to note that the development of a gene edited drug product involves a significant investment in the development of drugs in the field of gene research. In order to deliver these drugs efficiently, precisely and safely, the pharma companies are relying on new genome editing technologies developed by the genome editing companies, which in turn will help the drug developers in improving the clinical outcome by achieving the required genetic manipulation. With encouraging clinical trial results and accelerated drug approval, the market for genome editing is expected to experience significant growth over the next few years.

Key Market Segments

Type of Gene Editing Technique

  • CRISPR-Cas System
  • TALENs
  • Meganucleases
  • ZFNs
  • Other Techniques

Type of Therapy

  • Cell Therapies
  • Gene Therapies
  • Other Therapies
  • Gene Editing Approach
  • Gene Knock-Out Approaches
  • Gene Knock- In Approaches
  • Gene Delivery Method
  • Ex-Vivo Delivery Methods
  • In-Vivo Delivery Methods
  • Gene Delivery Modality
  • Viral Vectors
  • Non-Viral Vectors
  • Application Area
  • Drug Discovery and Development
  • Diagnostics

Type of End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Payment Method Employed
  • Upfront Payments
  • Milestone Payments

Research Coverage:

The report studies the genome editing market based on type of gene editing technique, type of therapy, gene editing approach, gene delivery method, gene delivery modality, application area, type of end user, key geographical regions and payment method employed.

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to three major regions

The report includes a brief introduction to genome editing, including the evolution of the domain over the years, a list of the different genome editing technologies, and an overview of how genome editing is being used in different industries such as biotechnology, pharma and agriculture. It also highlights the various cutting-edge genome editing technologies.

Comprehensive analysis of the current technology landscape for genome editing domain considering parameters such as type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported, therapeutic area and application. In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, establishment year, company size, headquarters and operational model

Create detailed profiles of leading genome editing companies, including establishment year, employees, HQ location, key executives, technology portfolios, recent developments, and future outlook.

Detailed company competitiveness evaluation of medical aesthetics company, considering developer strength and technology strength in terms of type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area.

Examine partnerships (licensing agreements, research and development agreements, technology integration agreements, etc.) in the genome editing market from 2018-2023. Analyze recent investments (grants, funding rounds) and initiatives by market stakeholders.

Review patents related to genome editing from 2018-2023, highlighting types, publication years, locations, CPC symbols, focus areas, applicant types, and leading players.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the genome editing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G+FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies

    OXGENE

  • Prime Medicine
  • Revvity (formerly known as Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past

Recessions and Lessons Learnt

      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Introduction to Genome Editing
    • 5.2.1. Evolution of Genome Editing
    • 5.2.2. Genome Editing Technologies
      • 5.2.2.1. CRISPR - Cas System
      • 5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
      • 5.2.2.3. Zinc Finger Nucleases (ZFNs)
      • 5.2.2.4. Meganucleases / Homing Endonucleases
  • 5.3. Applications of Genome Editing Technologies
  • 5.4. Other Emerging Technologies
  • 5.5. Concluding Remarks

6. TECHNOLOGY LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Genome Editing: Technology Landscape
    • 6.2.1. Analysis by Type of Gene Editing Technique
    • 6.2.2. Analysis by Gene Editing Approach
    • 6.2.3. Analysis by Type of Gene Delivery Method
    • 6.2.4. Analysis by Type of Gene Delivery Modality
    • 6.2.5. Analysis by Highest Phase of Drug Development Supported
    • 6.2.6. Analysis by Therapeutic Area
    • 6.2.7. Analysis by Application Area
  • 6.3. Genome Editing: Technology Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters
    • 6.3.4. Analysis by Operational Model
    • 6.3.5. Most Active Players: Distribution by Number of Technologies

7. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions / Key Parameters
  • 7.3. Methodology
  • 7.4. Technology Competitiveness Analysis
    • 7.4.1. Genome Editing Technologies Offered by Players based in North America
    • 7.4.2. Genome Editing Technologies Offered by Players based in Europe
    • 7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Arcturus Therapeutics
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Technology Portfolio
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Beam Therapeutics
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Technology Portfolio
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Caribou Biosciences
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Technology Portfolio
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Century Therapeutics
    • 8.5.1. Company Overview
    • 8.5.2. Financial Information
    • 8.5.3. Technology Portfolio
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. CRISPR Therapeutics
    • 8.6.1. Company Overview
    • 8.6.2. Financial Information
    • 8.6.3. Technology Portfolio
    • 8.6.4. Recent Developments and Future Outlook
  • 8.7. Editas Medicine
    • 8.7.1. Company Overview
    • 8.7.2. Financial Information
    • 8.7.3. Technology Portfolio
    • 8.7.4. Recent Developments and Future Outlook
  • 8.8. Graphite Bio
    • 8.8.1. Company Overview
    • 8.8.2. Technology Portfolio
    • 8.8.3. Recent Developments and Future Outlook
  • 8.9. Intellia Therapeutics
    • 8.9.1. Company Overview
    • 8.9.2. Financial Information
    • 8.9.3. Technology Portfolio
    • 8.9.4. Recent Developments and Future Outlook
  • 8.10. Prime Medicine
    • 8.10.1. Company Overview
    • 8.10.2. Technology Portfolio
    • 8.10.3. Recent Developments and Future Outlook
  • 8.11. Vor Biopharma
    • 8.11.1. Company Overview
    • 8.11.2. Technology Portfolio
    • 8.11.3. Recent Developments and Future Outlook
  • 8.12. Other Leading Players
    • 8.12.1. Avectas
    • 8.12.2. Bio-Sourcing
    • 8.12.3. Edigene
    • 8.12.4. Flash Therapeutics
    • 8.12.5. Fortgen
    • 8.12.6. G+FLAS Life Sciences
    • 8.12.7. Ntrans Technologies
    • 8.12.8. OXGENE
    • 8.12.9. Revvity (formerly known as Horizon Discovery)
    • 8.12.10. TargetGene Biotechnologies
    • 8.12.11. ZeClinics

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Genome Editing Technologies: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Location of Headquarters of Partner
    • 9.3.6. Most Active Players: Analysis by Number of Partnerships
    • 9.3.7. Analysis by Geography
      • 9.3.7.1. Local and International Agreements
      • 9.3.7.2. Intercontinental and Intracontinental Agreements

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Genome Editing Domain: Patent Analysis
    • 10.3.1. Analysis by Publication Year
    • 10.3.2. Analysis by Type of Patent and Publication Year
    • 10.3.3. Analysis by Geography
    • 10.3.4. Analysis by CPC Symbols
    • 10.3.5. Leading Industry Players: Analysis by Number of Patents
  • 10.4. Genome Editing Domain: Patent Benchmarking Analysis
    • 10.4.1. Analysis by Patent Characteristics
    • 10.4.2. Analysis by Leading Industry Players
  • 10.5. Patent Valuation Analysis

11. FUNDING AND INVESTMENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Types of Funding
  • 11.3. Genome Editing Domain: Funding and Investment Analysis
    • 11.3.1. Analysis by Year of Investment
      • 11.3.1.1. Cumulative Year-wise Trend of Funding Instances
      • 11.3.1.2. Cumulative Year-wise Trend of Amount Invested
    • 11.3.2. Analysis by Type of Funding
      • 11.3.2.1. Analysis of Funding Instances
      • 11.3.2.2. Analysis of Amount Invested
    • 11.3.3. Analysis by Year and Type of Funding
    • 11.3.4. Analysis by Geography
    • 11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
    • 11.3.6. Leading Investors: Analysis by Number of Funding Instances

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 12.1. Chapter Overview
  • 12.2. Market Drivers
  • 12.3. Market Restraints
  • 12.4. Market Opportunities
  • 12.5. Market Challenges
  • 12.6. Conclusion

13. GENOME EDITING TECHNOLOGIES MARKET

  • 13.1. Chapter Overview
  • 13.2. Assumptions and Methodology
  • 13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
    • 13.3.1. Scenario Analysis
  • 13.4. Key Market Segmentations
  • 13.5. Dynamic Dashboard

14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
  • 14.4. TALENs: Forecasted Estimates (2023-2035)
  • 14.5. Meganucleases: Forecasted Estimates (2023-2035)
  • 14.6. ZFNs: Forecasted Estimates (2023-2035)
  • 14.7. Other Techniques: Forecasted Estimates (2023-2035)
  • 14.8. Data Triangulation
    • 14.8.1. Insights from Primary Research
    • 14.8.2. Insights from Secondary Research
    • 14.8.3. Insights from In-house Repository

15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Cell Therapies: Forecasted Estimates (2023-2035)
  • 15.4. Gene Therapies: Forecasted Estimates (2023-2035)
  • 15.5. Other Therapies: Forecasted Estimates (2023-2035)
  • 15.6. Data Triangulation
    • 15.6.1. Insights from Primary Research
    • 15.6.2. Insights from Secondary Research
    • 15.6.3. Insights from In-house Repository

16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
  • 16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
  • 16.5. Data Triangulation
    • 16.5.1. Insights from Primary Research
    • 16.5.2. Insights from Secondary Research
    • 16.5.3. Insights from In-house Repository

17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
  • 17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
  • 17.5. Data Triangulation
    • 17.5.1. Insights from Primary Research
    • 17.5.2. Insights from Secondary Research
    • 17.5.3. Insights from In-house Repository

18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Viral Vectors: Forecasted Estimates (2023-2035)
  • 18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
  • 18.5. Data Triangulation
    • 18.5.1. Insights from Primary Research
    • 18.5.2. Insights from Secondary Research
    • 18.5.3. Insights from In-house Repository

19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
  • 19.4. Diagnostics: Forecasted Estimates (2023-2035)
  • 19.5. Data Triangulation
    • 19.5.1. Insights from Primary Research
    • 19.5.2. Insights from Secondary Research
    • 19.5.3. Insights from In-house Repository

20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
  • 20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
  • 20.5. Data Triangulation
    • 20.5.1. Insights from Primary Research
    • 20.5.2. Insights from Secondary Research
    • 20.5.3. Insights from In-house Repository

21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. North America: Forecasted Estimates (2023-2035)
  • 21.4. Europe: Forecasted Estimates (2023-2035)
  • 21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
  • 21.6. Data Triangulation
    • 21.6.1. Insights from Primary Research
    • 21.6.2. Insights from Secondary Research
    • 21.6.3. Insights from In-house Repository

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Milestone Payments: Forecasted Estimates (2023-2035)
  • 22.4. Upfront Payments: Forecasted Estimates (2023-2035)
  • 22.5. Data Triangulation
    • 22.5.1. Insights from Primary Research
    • 22.5.2. Insights from Secondary Research
    • 22.5.3. Insights from In-house Repository

23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS

  • 23.1. Chapter Overview
  • 23.2. Leading Industry Players

24. CONCLUSION

25. EXECUTIVE INSIGHTS

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS